The clinical impact of recent advances in LC-MS for cancer biomarker discovery and verification
Mass spectrometry-based proteomics has become an indispensable tool in biomedical research with broad applications ranging from fundamental biology, systems biology, and biomarker discovery. Recent advances in LC-MS have made it become a major technology in clinical applications, especially in cancer biomarker discovery and verification. To overcome the challenges associated with the analysis of clinical samples, such as extremely wide dynamic range of protein concentrations in biofluids and the need to perform high throughput and accurate quantification, significant efforts have been devoted to improve the overall performance of LC-MS bases clinical proteomics. In this review, we summarize the recent advances in LC-MS in the aspect of cancer biomarker discovery and quantification, and discuss its potentials, limitations, and future perspectives.
- Research Organization:
- Pacific Northwest National Lab. (PNNL), Richland, WA (United States). Environmental Molecular Sciences Lab. (EMSL)
- Sponsoring Organization:
- USDOE
- DOE Contract Number:
- AC05-76RL01830
- OSTI ID:
- 1243218
- Report Number(s):
- PNNL-SA-113659; 48505; 400412000
- Journal Information:
- Expert Review of Proteomics, Vol. 13, Issue 1; ISSN 1478-9450
- Publisher:
- Taylor & Francis
- Country of Publication:
- United States
- Language:
- English
Similar Records
Mass Spectrometry-Based Approaches for Clinical Biomarker Discovery in Traumatic Brain Injury
Advances and Challenges in Liquid Chromatography-Mass Spectrometry-Based Proteomics Profiling for Clinical Applications